Imatinib tablets | China Drugs List
Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.
Others
- Brand
- Gleevec / Glivec
- Company
- Novartis Europharm Limited (EU authorization holder)
- Medicine type
- Chemical medicine
- Therapeutic area
- Oncology
- Indications recorded in the public source
- European Union source summary: Selected uses include Philadelphia-chromosome-positive chronic myeloid leukemia; newly diagnosed Ph-positive acute lymphoblastic leukemia with chemotherapy, or relapsed/refractory adult disease as monotherapy; PDGFR-rearranged myelodysplastic/myeloproliferative disease; FIP1L1-PDGFR-alpha-associated hypereosinophilic syndrome or chronic eosinophilic leukemia; KIT-positive unresectable/metastatic gastrointestinal stromal tumors and adjuvant treatment when relapse risk is significant; and specified unresectable or recurrent/metastatic dermatofibrosarcoma protuberans. Age and prior-treatment requirements vary by indication.
- Indication source and scope
- European Union product information accessed 2 November 2026; exact revision date not separately extracted.. Selected overseas indications; does not establish the Chinese approved scope.
- Prescribing-information limitations
- Overseas official prescribing information linked; a complete current Chinese label has not been verified.
- China availability status
- Chinese approval, current approved indications and continuous market availability have not been independently verified in this English-source review.
- Overseas status
- See the linked overseas regulator / manufacturer evidence. Approval and indications are jurisdiction-specific; current supply is not established.
- Insurance classification
- Not yet verified
- Insurance edition
- Chinese national insurance review pending
- Insurance verification notes
- No reimbursement determination was made for this addition; missing information is not proof of exclusion.
Sources
- https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf
- Gleevec / Glivec — official European Union product information
Official prescribing information · European Union product information accessed 2 November 2026; exact revision date not separately extracted.
Full official PDF opened; medicine identity and relevant indication text checked. This overseas source does not establish the Chinese approved scope.
- Glivec — EMA assessment and product overview
Regulatory product overview · Accessed 2 November 2026
English regulatory reference; authorization holder is identified for the EU product, not a Chinese generic or biosimilar.
Evidence reviewed:
Open the interactive record, public price references and discussions